OncoMatch/Clinical Trials/NCT06389123
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
Is NCT06389123 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. for metastatic cancer.
Treatment: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. — This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — metastatic
documented tumor progression for metastatic disease during or following at least one prior FDA approved systemic regimen (Androgen Deprivation allowed)
Cannot have received: external beam radiation therapy
External beam radiation therapy (EBRT) or radiopharmaceutical treatment within 21 days prior to study day 1
Cannot have received: radiopharmaceutical treatment
External beam radiation therapy (EBRT) or radiopharmaceutical treatment within 21 days prior to study day 1
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1000 cells/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin ≥ 8 g/dL
Kidney function
Creatinine ≤ 2 times ULN
Liver function
AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN); Total bilirubin ≤ 2 times ULN
Cardiac function
No Class 3 or 4 NYHA Congestive Heart Failure
Hematologic parameters defined as: ANC ≥ 1000 cells/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 8 g/dL; Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5x ULN; Total bilirubin ≤ 2x ULN; Creatinine ≤ 2x ULN; Participants with Class 3 or 4 NYHA Congestive Heart Failure [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06389123 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior external beam radiation therapy, radiopharmaceutical treatment disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify